Mahamaya Lifesciences Ltd

Mahamaya Lifesciences Limited submitted a certificate to the BSE Limited on October 8, 2026, detailing securities dematerialized and rematerialized for the quarter ended September 30, 2026, as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, with KFin Technologies Limited acting as the registrar and share transfer agent.

Mahamaya Lifesciences Limited announced changes to its management, effective November 1, 2026, including the re-designation of Krishnamurthy Ganesan from Managing Director to Chairman and the re-designation of Prashant Krishnamurthy as Managing Director. The company also approved the regularization and appointment of Dr. Bhagirath Choudhary as Independent Director for a three-year term starting August 25, 2026, and the re-appointment of both Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee as Independent Directors for second three-year terms beginning December 11, 2026.

Mahamaya Lifesciences Limited informed the BSE Limited that the trading window for dealing in the company's securities will be closed for all insiders, designated persons, and their immediate relatives from October 01, 2026, until 48 hours after the declaration of the un-audited financial results (standalone and consolidated) for the half year ended September 30, 2026, with the date of the board meeting to consider and approve the results to be announced later.

Mahamaya Lifesciences Limited announced that an investor presentation will be shared during an investor meet scheduled for Friday, August 07, 2026, beginning at 04:00 pm (IST), and is available on the company’s website at https://www.mahamayalifesciences.com/shareholder, according to a regulatory filing with the BSE Limited.

Mahamaya Lifesciences will hold a meeting of the Board of Directors of the Company on 25 May 2026.

Mahamaya Lifesciences will hold a meeting of the Board of Directors of the Company on 2 December 2025.Powered by Capital Market - Live

The scrip was listed at Rs 116, a premium of 1.75% over the initial public offer (IPO) price. The stock is currently frozen at its lower limit of 5% over its listing price. The counter hit a high of Rs 121.80 and a low of Rs 115.50. About 18.98 lakh shares of the company changed hands at the counter. Mahamaya Lifesciences's IPO was subscribed 1.59 times. The issue opened for bidding on 11 November 2025 and it closed on 13 October 2025. The price band of the IPO was fixed between Rs 108 to Rs 114 per share. The IPO comprised 61,78,800 equity shares, including a fresh issue of 56,38,800 equity shares and offer for sale (OFS) of 5,40,000 equity shares. The promoter and promoter group shareholding diluted to 56.35% from 77.27% pre-issue. The company intends to utilize the net proceeds for purchase of equipment for existing formulation plant, funding capital expenditure towards setting up of a new technical manufacturing plant, construction of warehouse building and purchase of machinery, funding working capital requirement of the company and general corporate purposes. Ahead of the IPO, Mahamaya Lifesciences on 10 November 2025, raised Rs 19.97 crore from anchor investors. The board allotted 17.52 lakh shares at Rs 114 each to 7 anchor investors. Mahamaya Lifesciences specializes in the manufacturing of pesticide formulations and supplies bulk formulations to both Indian agrochemical companies and multinational corporations (MNCs). As of 30 September 2025, the company had 78 employees on its payroll. The company recorded revenue from operations of Rs 83.01 crore and net profit of Rs 4.10 crore for the period ended 30 June 2025. Powered by Capital Market - Live

The equity shares of Mahamaya Lifesciences (Scrip Code: 544611) are listed effective 18 November 2025 and admitted to dealings on the Exchange in the list of ''MT'' group securities. At 10:07 IST, the stock was trading at a premium of 1.75% to the issue price of Rs 114. Powered by Capital Market - Live